Soraienen has advised Vsquared Ventures on participating in the EUR 4.5 million seed investment round into Droplet Genomics.
Practica Capital and Meta Planet participated in the round as well.
According to Sorainen, the Droplet Genomics start-up will from now on “be known under the name Atrandi Biosciences. Established in 2016, the Lithuanian start-up intends to accelerate development by setting up a team in the United States and continuing the commercialization of droplet microfluidics and single-cell research technologies. Micro-droplet technology replaces test-tube research with droplets and can be applied in basic research or the search for new drugs.”
Sorainen’s team included Partner Mantas Petkevicius, Senior Associates Matas Maciuslaitis, Aurelija Daubaraite, and Sidas Sokolovas, and Associates Goda Jakubauskaite, Izabele Petrikaite, and Simonas Slitas.
Sorainen did not respond to our inquiry on the matter.
